Skip to content
Summer 2026 · 26% off every plan with SUMMER26 See pricing
Optionomics
BTMD · 10-Q filed August 7, 2026

BTMD earnings analysis

What we found in BTMD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.

Our reading of the filing · Free to read, no account needed

BTMD reported Q2 2026 revenue of $44.232 million and diluted EPS of $(0.23), with revenue declining from both the prior quarter and prior-year quarter and EPS materially missing the $0.08 consensus estimate. The quarter also included a $5.1 million legal-settlement charge and continued share repurchases of $4.8 million. The most significant governance concern is that disclosure controls remained ineffective as of June 30, 2026 because the previously reported material weakness had not been remediated; management provided no quantitative guidance in the supplied 10-Q text.

What stood out

The parts that mattered.

Pulled out of the filing itself, with the figures the company reported.

Revenue declined sequentially and year over year
Second-quarter revenue was $44.232 million, down from $45.0 million in Q1 2026 and $49.0 million in Q2 2025, a sequential decline of approximately 1.7% and year-over-year decline of approximately 9.7%.
EPS turned negative and missed estimates
Reported diluted EPS was $(0.23), versus $0.06 in Q1 2026 and $0.10 in Q2 2025. EPS missed the $0.08 consensus estimate by $0.31 per share.
Share repurchases continued
The company repurchased 2,436,177 Class A shares for $4.8 million during Q2 2026, at an average price of $2.05 per share.
Remaining buyback authorization
Approximately $5.2 million remained available under the $20.0 million share repurchase authorization as of June 30, 2026.
Right Value litigation payment completed
The company paid the remaining amount due under the $5.0 million Right Value settlement in February 2026, resolving that litigation subject to customary mutual releases.
What to watch

And the other side of it.

The offsets in the same document — the things a summary that only listed the good news would have left out.

Material weakness remains unresolved
Disclosure controls were concluded to be ineffective as of June 30, 2026 because a previously reported material weakness remained unremediated. The weakness originated from insufficient technical accounting personnel and information-technology control deficiencies identified for fiscal years 2020 and 2019, and it contributed to errors in the June 30, 2022 and September 30, 2022 quarterly filings.
Settlement charges pressure results
The company recorded a $5.1 million charge for legal settlements in both the three and six months ended June 30, 2026; the amount was included in accrued liabilities at June 30, 2026.
Buybacks may constrain liquidity
The company repurchased 2,436,177 shares for $4.8 million in Q2 while reporting $(0.23) diluted EPS, leaving only $5.2 million under the authorization. Continued repurchases may reduce liquidity while earnings are negative.
The numbers

What they reported.

What the company itself reported, taken out of the document.

Earnings per share
$-0.23
Guidance

What they said about what is next.

The supplied 10-Q text does not provide quantitative revenue or EPS guidance. The prior outlook was revenue exceeding $190.0 million for 2026, but this filing excerpt does not explicitly reaffirm or change it.

How we read the filing overall

The filing reads worse than the one before it.

One reading of one document. It is not advice, and it is not a forecast.
Earlier filings

What came before.

10-Q · May 11, 2026
Biote Corp. reported Q1 2026 financial results with revenues of $44.9 million, representing a decline of 8.3% year-over-year and missing analyst expectations, while EPS was $0.06, falling short of the estimated $0.08.…
10-Q · November 12, 2024
Biote reported Q3 revenue of $51.384M (three months ended Sept 30, 2024) and diluted EPS of $0.33, driven by product revenue of $49.806M and improved margins. Gross margin expanded to ~70.5% and operating margin to…
10-Q · August 15, 2022
biote Corp. reported quarterly revenue of $41,359 (amounts in thousands) for the three months ended June 30, 2022, up from $34,750 in the prior-year quarter, driven by product revenue of $40,789. Despite top-line growth…
10-Q · November 24, 2021
Haymaker Acquisition Corp. III reported net income of $2,995,085 for the three months ended September 30, 2021 (nine months net income $12,290,535), driven primarily by non‑operating fair value gains on warrant…

This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.

Read the next one first.

We read every filing BTMD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.

Cancel anytime · Month to month · Switch tiers whenever